Clinical and Instrumental Evaluation on Definisse Threads (FREE)

Face REshaping Effect With Definisse Threads: Clinical and Instrumental Evaluation ( FREE Study)

The scope of this clinical trial is to evaluate and confirm thereshaping effect of the face with Definisse Threads double needle and Definisse threads free floating insertion, at day 30. 6 clinical follow up visit will be performed

Study Overview

• Status: Completed
• Conditions: Face
• Intervention / Treatment: Device: Definisse threads free floating and definisse threads double needle

Detailed Description

The scope of this clinical trial is to evaluate and confirm thereshaping effect of the face with Definisse Threads double needle and Definisse threads free floating insertion, at day 30. 6 clinical follow up visit will be performed to evaluate the modification of skin surface characteristics, the reshaping effect of the face, the subject's satisfaction at each visit, the presence/absence of the threads after the implantation and the global pain perception during the implant procedure..

• Study Type: Interventional
• Enrollment (Actual): 28
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Salvatore Fundarò; Phone Number: 051 320 862; Email: dr.fundaro@gmail.com

Study Locations

• Italy
  • Italia
    • Bologna, Italia, Italy, 40129
      • MULTIMED poliambulatorio and day surgery

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 30 years to 60 years (Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Women, aged between 30 and 60 years (inclusive), looking for aesthetic procedures to improve the aspect of their midface and lower face.
2. Caucasian race.
3. Subjects, as per Investigator's assessment, with the degree of laxity in the middle and lower face belonging to 1-7 classes (inclusive), according to the Facial Laxity Rating Scale.
4. Subjects calm and controlled, according to the Investigator's opinion.
5. Subjects with cooperative attitude, able to comprehend the full nature and the purpose of the investigation, including possible risks, side effects and discomforts and willing to adhere to the study schedule (including attendance to the planned visits) and study prescriptions.
6. Written informed consent release prior to any study-related procedures

Exclusion Criteria:

Absolute exclusion criteria

Subjects presenting one or more of the following absolute exclusion criteria will not be eligible to enter the study.

1. Pregnant and breast-feeding women.
2. Subjects affected by body dysmorphic disorders.
3. Subjects with known allergy/hypersensitivity to threads components and/or lidocaine and/or clarithromycin.
4. Subjects with chronic urticaria.
5. Subjects with Quincke's edema.
6. Subjects with facial plastic surgery within previous 2 years.
7. Subjects with haemostatic or coagulation disorders (haemophilia, haemoglobin pathology, thalassemia major).
8. Subjects with active localized infection (ear, nose, or throat infections, dental abscess, periodontitis), active generalized infection (gastroenteritis, urinary bladder infection) or systemic infection (example: tuberculosis).
9. Subjects with generalized skin conditions or connective tissue disease (prominent scars, keloid, bullous diseases, cutaneous collagenosis, active psoriasis, connective tissue diseases).
10. Subjects with parotid hypertrophy.
11. Immunocompromised, oncological, diabetic subjects or with active Hashimoto's disease.
12. Subjects who underwent dental procedures within previous 2 weeks.
13. Subjects with conditions potentially causing a Koebner response.
14. Subjects with surgical medical treatments previously performed in the implant area or in the surrounding areas within previous 2 months.
15. Subjects with permanent or semi-permanent implants in the area that will be treated.
16. Subjects with active skin infection (impetigo, herpes simplex, massive demodex folliculorum, Pityrosporum, Propionibacterium acnes, viral warts).
17. Obesity.
18. Subjects who are hard smokers (more than 19 cigarettes/day).
19. Any other clinical condition that upon the judgement of the Investigator contraindicates the treatment with threads.

Relative exclusion criteria

Subjects presenting with one or more of the following relative exclusion criteria will be eligible to enter the study on the basis of the Investigator's evaluation.

1. Subjects with severe ptosis.
2. Anxious subjects.
3. Subjects with melasma and post-inflammatory hyperpigmentation.
4. Subjects with non-infectious gastrointestinal conditions like Crohn's disease or ulcerative colitis.
5. Subjects with hypertension, using anti-inflammatory and/or anticoagulant/antiaggregant medications.
6. Subjects who received filler injections or neurotoxin injection within the previous 2 months.
7. Subjects with inflammatory conditions of the skin.
8. Subjects who are mild-moderate smokers.
9. Subjects having menstruation during the day of the treatment.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Definisse threads free floating and Definisse threads double needle; Definisse™ free floating threads will be used with the Soft Tissue Reshaping-2 (STR-2) Technique, to reposition the tissue of the malar area. It is to be used for the face and neck. The thread presents a central area, free of barbs, and two distal areas with barbs. The 12 cm thread will be used in this study. Definisse™ double needle thread (12 cm) that is equipped with barbs in the intermediate section, while the side and the central sections are smooth. The thread ends with two straight cut edge needles 10 cm long Definisse™ double needle threads will be used with the Jawline Reshaping (JR) Technique, to reshape the frame of the jawline, lifting the lower face. This is to be used for the face and the neck. The thread ends with two straight cut edge needles The 12 cm thread will be used in this study.

Device: Definisse threads free floating and definisse threads double needle; Definisse threads are two class III medical devices, for evaluate the performance of the reshaping effect of the face at day 30

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Volume of midface and lower face with Definisse threads double needle and Definisse threads free floating insertion at day 30	The primary objective of this clinical investigation is to evaluate the reshaping effect of the face with Definisse™ thread double needle and Definisse™ thread free floating insertion, at Day 30, through 3D photos and 2D photos, through VECTRA®H2	up to 30 days of treatment

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
reshaping effect between baseline and T15d, T4m, T8m, T12m.	To evaluate the reshaping effect of the face with Definisse™ threads between baseline and day 15, 4 months, 8 months, 12 months with GAIS (Global Aesthetic Improvement Scale; 5-item scale, where 1 = exceptional improvement, 2 = very improved, 3 = improved, 4 = unaltered, 5 = worsened.))	up to 15 days, 4 months, 8 months and 12 monts of tratment
To evaluate the modification of skin surface characteristics at 30 days, 4 months, 8 months and 12 monts from baseline	Modification of skin surface characteristics in terms of wrinkles, pores and texture, that will be evaluated and quantified at day 30d, 4 months, 8 months, 12 months from baseline through ANTERA 3D.	up to 30 days, 4 months, 8 months and 12 monts of tratment
to evaluate the subject's satisfaction at each visit (1 day, 15 days, 30 days, 4 months, 8 months and 12 monts)	Subject's satisfaction self-assessment on the reshaping effect according to the Global Aesthetic Improvement Scale (GAIS: 5-item scale, where 1 = exceptional improvement, 2 = very improved, 3 = improved, 4 = unaltered, 5 = worsened.) at each visit (1 day, 15 days, 30 days, 4 months, 8 months and 12 monts).	up to 1 day, 15 days, 30 days, 4 months, 8 monts and 12 months of treatment
To assess the clinical evaluation of reshaping effect of the total, middle and lower face comparing baseline to T15d, T30d, T4m, T8m, T12m by the non-treating investigators	Aesthetic changes of the total, middle and lower face according to the Global Aesthetic Improvement Scale (GAIS: 5-item scale, where 1 = exceptional improvement, 2 = very improved, 3 = improved, 4 = unaltered, 5 = worsened) by the non-treating investigators (one plastic surgeon and one dermatologist) as clinical evaluation of reshaping effect, comparing baseline to T15d, T30d, T4m, T8m, T12m, by evaluating the 2D photos collected by VECTRA®H2	up to 15 days, 30 days, 4 months,8 months, 12 months of treatment
To evaluate the presence/absence of the threads after the implantation at T30d, T4m, T8m, T12m	Presence/absence of the thread in the implant area after 30 days, 4 months, 8 months and 12 monts from the treatment with an ultrasound evaluation.	up to 30 days, 4 months, 8 months, 12 months of treatment
To evaluate the global pain perception during the implant procedure at T1d and T15d.	Global pain perception during the implant procedure at 1 day and at the first follow-up visit (15 days) by a numeric pain scale (NRS: from "0" (No pain) to "10" (worst possible pain)).	up to 1 and 15 days of treatment
To evaluate the subject's self-esteem at each visit (1 day, 15 days, 30 days, 4 months, 8 months and 12 monts) T30d, T4m, T8m, T12m).	Subject's self-esteem by the Rosenberg Self-Esteem Scale at each visit ( This scale is a widely used self-report instrument for evaluating individual self-esteem. The scale ranges from 0 to 30. Scores between 15 and 25 are within normal range; scores below 15 suggest low self-esteem.)(1 day, 15 days, 30 days, 4 months, 8 months and 12 monts)	up to 1 day, 15 ddays, 30 days, 4 months, 8 month, 12 months of treatment

Collaborators and Investigators

• Sponsor: Relife S.r.l.
• Investigators: Principal Investigator: Salvatore Fundarò, MULTIMED poliambulatorio and day surgery

Study record dates

Study Major Dates

• Study Start (Actual): November 6, 2021
• Primary Completion (Actual): February 21, 2023
• Study Completion (Actual): June 15, 2023

Study Registration Dates

• First Submitted: June 23, 2021
• First Submitted That Met QC Criteria: July 9, 2021
• First Posted (Actual): July 21, 2021

Study Record Updates

• Last Update Posted (Actual): June 22, 2023
• Last Update Submitted That Met QC Criteria: June 21, 2023
• Last Verified: April 1, 2022

More Information

Terms related to this study

• Other Study ID Numbers: ReGl/20/DTh-Rej/002

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No